Dosing tolerability and adverse events (AEs) in dihydropyrimidine dehydrogenase ( DPYD ) variant carriers receiving genotyping-guided fluoropyrimidine (FP) dosing.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.3095
Abstract: 3095 Background: We previously showed that DPYD genotype-guided FP (5-FU, capecitabine) dosing reduces severe AEs and hospitalizations in variant carriers. However, optimal dose reduction and tolerability for individual DPYD variants are not well understood. This… read more here.
Keywords: variant carriers; adverse events; dosing tolerability; dpyd variant ... See more keywords